Digging for data from the COX-2 trials [1]

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 13, 2002, Pages 1649-1650

  McCormack, James P ^a   Rangno, Robert ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; LETTER; TREATMENT OUTCOME;

EID: 0036080658     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Inaccessibility of drug reports
2. Understanding controlled trials: Why are randomised controlled trials important?
3. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
4. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
5. FDA refuses companies' request to drop ulcer warning
6. Reporting drug safety in clinical trials: Getting the emphasis right